NEW YORK, June 17, 2014 (GLOBE NEWSWIRE) -- Signal Genetics, Inc., an emerging commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the pricing of its initial public offering of 850,000 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Signal Genetics from the initial public offering are expected to be $8,500,000, before underwriting discounts and commissions and other offering expenses. Signal Genetics has granted the representative of the underwriters a 45-day option to purchase up to 127,500 additional shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on The NASDAQ Capital Market under the symbol "SGNL" on June 18, 2014 and the offering is expected to close on June 23, 2014, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 17, 2014.
This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: firstname.lastname@example.org. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in New York, New York, is an emerging commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Our mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. We were founded in January 2010 and became the exclusive licensee in our licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, or UAMS, in April 2010.
The Ruth Group